A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate
Status:
Completed
Trial end date:
2017-12-02
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability and blood concentrations of lasmiditan and
topiramate together compared to lasmiditan and topiramate separately. Information about any
side effects that may occur will be collected.
Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start
of the study and will remain through Day 14.
This study is expected to last approximately 25 days, not including screening. Screening is
required within 28 days prior to the start of the study.